



FORM PTO-1449  
(REV. 7-80)INFORMATION DISCLOSURE CITATION  
IN AN APPLICATIONATTY. DOCKET NO. KIR92-  
01A4

SERIAL NO. 08/690,775

APPLICANTS Marc Feldmann and Ravinder N. Maini

FILING DATE

August 1, 1996

GROUP

1806 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
M	A0 WO 92/16553	01-OCT-92	PCT			
M	AP WO 95/09652	13-APR-95	PCT			
M	AQ WO 96/33204	24-OCT-96	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M	AX3	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> , 7 :191-297 (1995).
M	AY3	Bologna, C., and Sany, J., "Association des Traitements de Fond dans la Polyarthrite Rhumatoide," <i>Presse Med.</i> , 25:876-878 (1996).
M	AZ3	Borigini, M.J., and Paulus, H.E., "Combination Therapy," <i>Baillière's Clin. Rheum.</i> , 9(4):689-710 (1995).
M	AR4	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> , 9:206-212 (1997).
M	AS4	Kavanaugh, A., et al., "Anti-TNF- $\alpha$ Monoclonal Antibody (mAb) Treatment of Rheumatoid Arthritis (RA) Patients With Active Disease On Methotrexate (MTX); Results of a Double-Blind, Placebo Controlled Multicenter Trial," <i>Arth. Rheum.</i> , 39(Suppl. 9): 18-22 (October 1996), Abstract 575.

EXAMINER

PHILLIP GRAMMEL

DATE CONSIDERED

8/25/98